Budesonide DR is a Small Molecule owned by Calliditas Therapeutics, and is involved in 15 clinical trials, of which 10 were completed, 3 are ongoing, and 2 are planned.

Budesonide (Nefecon, PL-56) is glucocorticoid receptor agonist. The drug candidate down regulates the inflammatory process in the kidneys through suppression of the gut immune system. Glucocorticoids suppress inflammation mainly by switching off multiple activated inflammatory genes through reversing histone acetylation through the recruitment of histone deacetylase-2 (HDAC2).

The revenue for Budesonide DR is expected to reach a total of $2.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Budesonide DR NPV Report.

Budesonide DR is currently owned by Calliditas Therapeutics. Everest Medicines is the other company associated in development or marketing of Budesonide DR.

Budesonide DR Overview

Budesonide (Tarpeyo, Kinpeygo) is a glucocorticoid that acts as an anti inflammatory agent. It is formulated as delayed release capsules and modified release hard capsules for oral route of administration. Tarpeyo is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. Kinpeygo is indicated for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram. 

Everest Medicines Overview

Everest Medicines, is a biopharmaceutical company that licenses, develops and commercializes medicines for the treatment of cancer, autoimmune, cardio renal and infectious diseases. It is investigating Sacituzumab govitecan, an antibody-drug conjugate targeting metastatic triple-negative breast cancer (mTNBC), metastatic urothelial cancer (mUc), non-small cell lung cancer (NSCLC) and other oncology indications; and FGF401 for hepatocellular carcinoma. The company is evaluating Etrasimod to treat ulcerative colitis and other autoimmune diseases; Nefecon for IgA nephropathy; Ralinepag against pulmonary arterial hypertension (PAH). Everest Medicines is also developing drugs for community-acquired bacterial pneumonia (CABP), complicated urinary tract infection (cUTi) and other infectious diseases. It works in partnership with Immunomedics, Novartis, Arena Pharmaceuticals and other companies to develop its products. Everest Medicines is headquartered in Shanghai, China.

The company reported revenues of (Renminbi) CNY0.1 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was CNY1,026.3 million in FY2021, compared to an operating loss of CNY688.5 million in FY2020. The net loss of the company was CNY1,008.7 million in FY2021, compared to a net loss of CNY5,658.2 million in FY2020.

Quick View – Budesonide DR

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Budesonide DR
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.